Evidence map›Paper›PMID 34402302›Full record

ArticleInorganic chemistry2021

Tuning Cyclometalated Gold(III) for Cysteine Arylation and Ligand-Directed Bioconjugation.

Sailajah Gukathasan, Sean Parkin, Esther P Black, Samuel G Awuah

Open access · greenAbstract read
In one paragraph

Article in Inorganic chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Ultrafast Au(III)-Mediated Arylation of Cysteine.Journal of the American Chemical Society · 2024
    Article
  7. Metal-Mediated Ligand Affinity Chemistry (MLAC).Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  8. Article
  9. OrganometallicBioconjugate chemistry · 2022
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sailajah GukathasanDepartment of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.
Sean ParkinDepartment of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.
Esther P BlackCenter for Pharmaceutical Research and Innovation, College of Pharmacy and Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536, United States.
Samuel G AwuahDepartment of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.ORCID https://orcid.org/0000-0003-4947-7283
University of Kentucky · US

Funding

Understanding the role of anti-apolipoprotein A-I antibodies in atherosclerotic cardiovascular diseaseP20GM130456 · NIGMS · UNIVERSITY OF KENTUCKY · PI M. Ashfaqul Alam · 2020 to 2026
$18.7M
NIGMS NIH HHS P20 GM130456
6 · The paper itself

Abstract

Transition-metal-based approaches to selectively modify proteins hold promise in addressing challenges in chemical biology. Unique bioorthogonal chemistry can be achieved with preformed metal-based compounds; however, their utility in native protein sites within cells remain underdeveloped. Here, we tune the ancillary ligands of cyclometalated gold(III) as a reactive group, and the gold scaffold allows for rapid modification of a desired cysteine residue proximal to the ligand binding site of a target protein. Moreover, evidence for a ligand association mechanism toward C-S bond formation by X-crystallography is established. The observed reactivity of cyclometalated gold(III) enables the rational design of a cysteine-targeted covalent inhibitor of mutant KRAS. This work illustrates the potential of structure-activity relationship studies to tune kinetics of cysteine arylation and rational design of metal-mediated ligand affinity chemistry (MLAC) of native proteins.

Indexed as

CysteineEnzyme InhibitorsGoldHumansLigandsMolecular StructureProto-Oncogene Proteins p21(ras)CysteineEnzyme InhibitorsGoldKRAS protein, humanLigandsProto-Oncogene Proteins p21(ras)

Identifiers

PMID34402302
PMCPMC8711130
OpenAlexW3194569689

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.